Galatek Corporation

Based in Singapore, Galatek Corporation engages in providing innovative technology solutions across the life sciences, healthcare, semiconductor, and sustainable energy sectors. Galatek Corporation, founded in 2025 and headquartered in Singapore, develops advanced technological solutions tailored for laboratory applications. The company has successfully completed 1 deal, raising USD 30 mn in Series A funding on December 19, 2025. The founder has a history in the technology sector, though specific previous ventures are not available.

Galatek is a technology-driven company specializing in innovative solutions primarily within the life sciences, healthcare, semiconductor, and sustainable energy sectors. The company's core offerings include advanced liquid handling workstations, high-content cell imaging systems, and proprietary 3D disease model technology, which facilitate precise and efficient analysis in laboratory settings. These products are engineered to meet the demands of high-throughput drug screening, cell gene editing, and various other applications in biotechnology and pharmaceuticals. Galatek serves a diverse client base that includes research institutions, pharmaceutical companies, and biotech firms across multiple geographical markets, including North America, Europe, and Asia-Pacific.

By addressing critical challenges in automation and precision, Galatek’s products enhance laboratory workflows and improve outcomes in scientific research and development efforts. Galatek operates on a business-to-business (B2B) model, providing its advanced products and solutions to institutional clients such as laboratories and research facilities. Revenue generation is primarily derived from direct sales of its flagship products, supported by strategic partnerships and collaboration agreements with entities in the life sciences and semiconductor sectors. The transaction structure typically involves direct orders for hardware, software licenses, and accompanying service agreements.

Clients may engage in long-term contracts that include maintenance and support services, ensuring optimal operational efficiency. While specific pricing plans for individual products or services are proprietary and not disclosed, the company positions its offerings as essential investments for organizations seeking to leverage cutting-edge technology in their research processes. In December 2025, Galatek Corporation raised USD 30 mn in Series A funding to support its product innovation and expansion plans. The company is designing upcoming products aimed at enhancing laboratory automation and efficiency, while also targeting expansion into new markets, including Europe and Asia-Pacific, by 2026.